**
Retatrutide vs tesamorelin comparison reveals that retatrutide is a triple‑receptor agonist still in Phase 3 trials, while tesamorelin is an FDA‑approved growth‑hormone‑releasing hormone analog for HIV‑associated lipodystrophy.
Key Facts
- Retatrutide (LY3437943) targets GLP‑1, GIP and glucagon receptors; Phase 3 NDA expected late 2026 【1†L1-L4】.
- Tesamorelin (Egrifta) is a synthetic GHRH analog approved for HIV‑associated visceral fat reduction; daily 2 mg dose 【2†L1-L4】.
- Average weight loss in retatrutide Phase 2 trials reached 28.7 % of body weight at 12 mg weekly 【1†L2-L4】.
- Monthly cost estimates: retatrutide $1,200‑$1,500; tesamorelin $200‑$1,500 【1†L3-L5】.
- Retatrutide is administered weekly; tesamorelin is administered daily 【1†L4-L5】.
What is retatrutide and how does it work?
Retatrutide is a synthetic peptide that simultaneously activates three metabolic hormone receptors: GLP‑1, GIP and glucagon. The GLP‑1 component suppresses appetite and delays gastric emptying. The GIP component improves insulin sensitivity and lipid handling. The glucagon component raises energy expenditure by stimulating hepatic fatty‑acid oxidation and thermogenesis in brown adipose tissue 【3†L1-L8】. This triple‑agonist design is the first of its kind and aims to produce greater weight loss than dual agonists such as tirzepatide.
What is tesamorelin and how does it work?
Tesamorelin is a synthetic analog of human growth‑hormone‑releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs, prompting pulsatile secretion of growth hormone (GH) and subsequent rise in IGF‑1. Elevated GH drives lipolysis preferentially in visceral adipose tissue, reducing deep‑abdominal fat that contributes to insulin resistance and cardiovascular risk 【3†L9-L15】.
How do efficacy outcomes compare?
In Phase 2 trials, retatrutide produced up to 28.7 % body‑weight reduction after 48 weeks at a 12 mg weekly dose 【1†L2-L4】. No comparable weight‑loss data exist for tesamorelin, whose primary indication is reduction of visceral fat in HIV‑positive patients, not overall weight loss 【1†L2-L3】. Tesamorelin trials showed a 15‑18 % decrease in trunk fat and improvements in hepatic steatosis markers 【3†L16-L19】.
| Metric | Retatrutide | Tesamorelin |
|---|---|---|
| Regulatory status | Phase 3 (NDA expected late 2026) | FDA‑approved (Egrifta) |
| Primary indication | Obesity & metabolic disease | HIV‑associated lipodystrophy |
| Dosing | 12 mg subcutaneous weekly (dose‑escalation) | 2 mg subcutaneous daily |
| Weight loss | ≈28.7 % body weight (48 weeks) | Not primary; ~15‑18 % trunk‑fat reduction |
| Cost (monthly) | $1,200‑$1,500 | $200‑$1,500 |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Injection‑site reactions, arthralgia, peripheral edema |
What are the safety profiles?
Retatrutide’s most frequent adverse events are gastrointestinal: nausea (up to 25 %), diarrhea (up to 22 %) and vomiting (up to 15 %). Severe gastrointestinal reactions and rare cases of pancreatitis have been reported 【2†L1-L4】. Tesamorelin’s side‑effects include injection‑site redness, joint pain, peripheral edema, and occasional elevation of blood glucose 【3†L20-L23】. Both agents carry warnings for potential neoplasm risk, though the data differ in frequency and severity 【1†L6-L8】.
Which patients are best suited for each peptide?
Retatrutide is aimed at adults with obesity or metabolic disease who need substantial weight loss and can tolerate weekly injections. It is still investigational, so access is limited to clinical‑trial participants or future commercial rollout. Tesamorelin is indicated for HIV‑positive patients with excess abdominal fat; it is also used off‑label for body‑composition goals but requires daily dosing and monitoring of glucose and IGF‑1 levels 【1†L1-L3】【3†L16-L18】.
How do the costs compare?
Estimated monthly price for retatrutide ranges from $1,200 to $1,500, reflecting its status as a research compound and anticipated premium pricing upon approval 【1†L3-L5】. Tesamorelin’s price varies widely, from $200 to $1,500 per month, depending on pharmacy, insurance coverage and manufacturer assistance programs 【1†L3-L5】. Patients should consult insurers and specialty pharmacies for exact out‑of‑pocket costs.
FAQ
Is retatrutide approved by the FDA?
No. Retatrutide is in Phase 3 trials with an NDA expected in late 2026 【1†L1-L4】.
Can tesamorelin be used for general weight loss?
Tesamorelin is approved only for HIV‑associated lipodystrophy; it is not indicated for overall weight loss 【1†L2-L3】.
How often must each peptide be injected?
Retatrutide is administered subcutaneously once weekly; tesamorelin is injected subcutaneously once daily 【1†L4-L5】.
What are the most common side effects?
Retatrutide: nausea, diarrhea, vomiting. Tesamorelin: injection‑site reactions, arthralgia, peripheral edema 【2†L1-L4】【3†L20-L23】.
Which peptide is more affordable?
Tesamorelin can be as low as $200 per month, while retatrutide starts around $1,200 per month 【1†L3-L5】.
Sources: PeptideVS – PeptidePatterns – Peptide Reference – PeptideBaseUpdated: November 10, 2026.
